NEWBURYPORT, MA--(Marketwired - October 07, 2013) -
PCI Synthesis, Inc. (www.pcisynthesis.com
), a custom chemical manufacturer of new chemical entities (NCE), generic active pharmaceutical ingredients (API's), complex pharmaceutical intermediates and other specialty products, announced that industry veteran Glenn Killingworth has joined the company as the Vice President of Business Development.
In his new role, Killingworth will drive business growth through the development and implementation of PCI's sales and marketing strategy, building and leading business development teams to embrace the next generation of new opportunities for PCI in both existing and new markets worldwide.
"Glenn's two decades of industry experience, including his track record in growing markets in Europe and the U.S., will be an important addition to PCI's senior management team. His success with emerging and mid-sized pharmaceutical companies in Europe, as well as in the U.S., will help the company continue its growth," said Ed Price, President of PCI Synthesis. "We've spent the past 18 months improving our organization, and the addition of Glenn is an important investment in our capabilities."
A specialist in the field of organic chemistry, Killingworth brings 25 years of experience working for specialist companies including Fisher Scientific, Peakdale Molecular, Almac Sciences, WuXi Apptec and Asymchem. Killingworth has spent the last decade in commercial and business development roles, developing a proven track record of sales achievements principally in the pharmaceutical R&D sector worldwide.
"PCI has a fine balance of scientific, manufacturing and quality disciplines essential to success in supporting the demands of its client's new pharmaceutical development pipelines and manufacturing needs. The dedication of the staff, their ethical approach to intellectual property and client communication, and their application of an outstanding science base is at the heart of my vision for driving the company's growth," said Killingworth.
Born in the U.K., Killingworth graduated from the University in Manchester with a degree in Applied Organic Chemistry, and worked in organic chemical research and process development for almost 10 years before moving into business development. He will be based in the company's Newburyport headquarters.
About PCI Synthesis
PCI Synthesis is a 15-year-old custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products. A contract manufacturing organization (CMO), PCI provides small and mid-sized companies with expertise needed to manufacture complex small molecules to be used in both the branded and generic market. To learn more about PCI Synthesis, its proprietary APIs, and R&D, please visit www.pcisynthesis.com.